[
  {
    "ts": null,
    "headline": "Big Tech and Pharma Earnings: What to Watch This Week",
    "summary": "Earnings season marches on this week. Two more Magnificent Seven tech companies—Alphabet and Amazon—will report, following on the heels of disappointing results from Microsoft that helped send software stocks tumbling last week.",
    "url": "https://finnhub.io/api/news?id=c28a9c55f89b6e4ee3a2cc078c7c5c981f88e6e147d5c4b3cf134c4c4ad2d164",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770073343,
      "headline": "Big Tech and Pharma Earnings: What to Watch This Week",
      "id": 138337200,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Earnings season marches on this week. Two more Magnificent Seven tech companies—Alphabet and Amazon—will report, following on the heels of disappointing results from Microsoft that helped send software stocks tumbling last week.",
      "url": "https://finnhub.io/api/news?id=c28a9c55f89b6e4ee3a2cc078c7c5c981f88e6e147d5c4b3cf134c4c4ad2d164"
    }
  },
  {
    "ts": null,
    "headline": "Equities Rise as Focus Shifts to Busy Earnings Week",
    "summary": "US equity benchmarks rose Monday as investors geared up for more earnings reports this week, includi",
    "url": "https://finnhub.io/api/news?id=1edfd6408a2b8af2f091d9a7776f070bc4d32086e8ff99dc3a8de370be7d17d4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770069132,
      "headline": "Equities Rise as Focus Shifts to Busy Earnings Week",
      "id": 138336188,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "US equity benchmarks rose Monday as investors geared up for more earnings reports this week, includi",
      "url": "https://finnhub.io/api/news?id=1edfd6408a2b8af2f091d9a7776f070bc4d32086e8ff99dc3a8de370be7d17d4"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Believes Novo Nordisk “Is a Hold, Not a Buy”",
    "summary": "Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer shared his thoughts on. The first caller of the episode inquired about the stock, and Cramer replied: I kind of liked it when I spoke to them. I gotta tell you, I kind of warmed up… I was in San Francisco, and I said, […]",
    "url": "https://finnhub.io/api/news?id=2b00a4501e810a535eda694f85bd8fdb3e13a86c9598ac9803833741ddea31db",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770063499,
      "headline": "Jim Cramer Believes Novo Nordisk “Is a Hold, Not a Buy”",
      "id": 138336245,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer shared his thoughts on. The first caller of the episode inquired about the stock, and Cramer replied: I kind of liked it when I spoke to them. I gotta tell you, I kind of warmed up… I was in San Francisco, and I said, […]",
      "url": "https://finnhub.io/api/news?id=2b00a4501e810a535eda694f85bd8fdb3e13a86c9598ac9803833741ddea31db"
    }
  },
  {
    "ts": null,
    "headline": "Equities Rise Intraday as Markets Await Key Earnings; Oil Tumbles",
    "summary": "US benchmark equity indexes were higher after midday Monday, while oil prices slumped as investors a",
    "url": "https://finnhub.io/api/news?id=2ddafc48e00d3bf0ed868fb1862879cdf072d15bea6571b045e157f26f93bda4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770060017,
      "headline": "Equities Rise Intraday as Markets Await Key Earnings; Oil Tumbles",
      "id": 138335014,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "US benchmark equity indexes were higher after midday Monday, while oil prices slumped as investors a",
      "url": "https://finnhub.io/api/news?id=2ddafc48e00d3bf0ed868fb1862879cdf072d15bea6571b045e157f26f93bda4"
    }
  },
  {
    "ts": null,
    "headline": "Is Novo Nordisk Stock a Bargain Right Now?",
    "summary": "Novo Nordisk just introduced a GLP-1 pill, but the company makes more than just weight-loss drugs.",
    "url": "https://finnhub.io/api/news?id=667b45bc10568b2bf28d082659055c4a650e479ec02bb558bbad45dcd686a2bd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770059280,
      "headline": "Is Novo Nordisk Stock a Bargain Right Now?",
      "id": 138335059,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk just introduced a GLP-1 pill, but the company makes more than just weight-loss drugs.",
      "url": "https://finnhub.io/api/news?id=667b45bc10568b2bf28d082659055c4a650e479ec02bb558bbad45dcd686a2bd"
    }
  },
  {
    "ts": null,
    "headline": "Revvity Q4 Earnings Call Highlights",
    "summary": "Revvity (NYSE:RVTY) executives said the company ended 2025 with results that exceeded internal expectations, helped by better-than-anticipated performance in diagnostics and improving trends in parts of the life sciences portfolio. Management also provided an initial 2026 outlook that assumes recent",
    "url": "https://finnhub.io/api/news?id=40524c9a0f3661efcf6b177f330943bb7520197d341b932c346733394dfa2f3d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770054734,
      "headline": "Revvity Q4 Earnings Call Highlights",
      "id": 138334006,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Revvity (NYSE:RVTY) executives said the company ended 2025 with results that exceeded internal expectations, helped by better-than-anticipated performance in diagnostics and improving trends in parts of the life sciences portfolio. Management also provided an initial 2026 outlook that assumes recent",
      "url": "https://finnhub.io/api/news?id=40524c9a0f3661efcf6b177f330943bb7520197d341b932c346733394dfa2f3d"
    }
  },
  {
    "ts": null,
    "headline": "S&P 500 Companies' Quarterly Earnings Tracking Well Above Views, Oppenheimer Says",
    "summary": "S&P 500 companies' fourth-quarter earnings are so far tracking well above expectations, Oppenheimer",
    "url": "https://finnhub.io/api/news?id=400fad148cc4acde878c98e5234d4bfd928f9113396e2ff86bff3c273cf12849",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770051666,
      "headline": "S&P 500 Companies' Quarterly Earnings Tracking Well Above Views, Oppenheimer Says",
      "id": 138333641,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "S&P 500 companies' fourth-quarter earnings are so far tracking well above expectations, Oppenheimer",
      "url": "https://finnhub.io/api/news?id=400fad148cc4acde878c98e5234d4bfd928f9113396e2ff86bff3c273cf12849"
    }
  },
  {
    "ts": null,
    "headline": "Merck Reports Earnings Tuesday Morning After Gaining 13% Over the Past Year",
    "summary": "Merck & Co. reports Q4 2025 earnings on Tuesday, Feb. 3, 2026, before market open. Wall Street expects earnings of $2.01 per share on revenue of $16.12 billion, representing 3.1% year-over-year growth. Shares have gained 13% over the past year, outperforming the healthcare sector’s broader returns. Here’s what investors should watch for. The Numbers That ... Merck Reports Earnings Tuesday Morning After Gaining 13% Over the Past Year",
    "url": "https://finnhub.io/api/news?id=fc6b924cd698a23a500b25032cd8f15b3b7caa244fd3482ff96ffe6497c82f0a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770050424,
      "headline": "Merck Reports Earnings Tuesday Morning After Gaining 13% Over the Past Year",
      "id": 138333682,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Merck & Co. reports Q4 2025 earnings on Tuesday, Feb. 3, 2026, before market open. Wall Street expects earnings of $2.01 per share on revenue of $16.12 billion, representing 3.1% year-over-year growth. Shares have gained 13% over the past year, outperforming the healthcare sector’s broader returns. Here’s what investors should watch for. The Numbers That ... Merck Reports Earnings Tuesday Morning After Gaining 13% Over the Past Year",
      "url": "https://finnhub.io/api/news?id=fc6b924cd698a23a500b25032cd8f15b3b7caa244fd3482ff96ffe6497c82f0a"
    }
  },
  {
    "ts": null,
    "headline": "Market Awaits January Manufacturing Numbers",
    "summary": "Market Awaits January Manufacturing Numbers.",
    "url": "https://finnhub.io/api/news?id=eb4169eae1051f11a4ac5c43bcde5a5a3934fd0dcd63bb08342cadf86a4b4ed1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770048720,
      "headline": "Market Awaits January Manufacturing Numbers",
      "id": 138333980,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Market Awaits January Manufacturing Numbers.",
      "url": "https://finnhub.io/api/news?id=eb4169eae1051f11a4ac5c43bcde5a5a3934fd0dcd63bb08342cadf86a4b4ed1"
    }
  },
  {
    "ts": null,
    "headline": "AZN Obesity Pipeline to Get a Boost From Deal With China's CSPC",
    "summary": "AstraZeneca deepens its obesity push with an eight-program deal with China's CSPC, securing rights to a once-monthly injectable weight-management pipeline.",
    "url": "https://finnhub.io/api/news?id=0062b7863f8b94b996f25130761f8833d55705edadf09c30df784d5c9ad4dd05",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770048000,
      "headline": "AZN Obesity Pipeline to Get a Boost From Deal With China's CSPC",
      "id": 138334568,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "AstraZeneca deepens its obesity push with an eight-program deal with China's CSPC, securing rights to a once-monthly injectable weight-management pipeline.",
      "url": "https://finnhub.io/api/news?id=0062b7863f8b94b996f25130761f8833d55705edadf09c30df784d5c9ad4dd05"
    }
  },
  {
    "ts": null,
    "headline": "Six More Weeks of Q4 Earnings Season?",
    "summary": "We're quiet to start a new trading week, but this is both Jobs Week and the busiest Q4 earnings week thus far.",
    "url": "https://finnhub.io/api/news?id=75c490e073137a7621df073f470432a31ad27c922d63f02245912cd99f3efd1e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770046500,
      "headline": "Six More Weeks of Q4 Earnings Season?",
      "id": 138333683,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We're quiet to start a new trading week, but this is both Jobs Week and the busiest Q4 earnings week thus far.",
      "url": "https://finnhub.io/api/news?id=75c490e073137a7621df073f470432a31ad27c922d63f02245912cd99f3efd1e"
    }
  },
  {
    "ts": null,
    "headline": "What's in Store for These 5 Pharma Bigwigs This Earnings Season?",
    "summary": "As earnings season accelerates, pharma heavyweights LLY, MRK, NVO, BMY and PFE prepare to reveal their Q4 results amid a strong sector start.",
    "url": "https://finnhub.io/api/news?id=80649950b33082b20364be17e694b012330a1b2a8b254d291dc2e8103f26dbe0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770045900,
      "headline": "What's in Store for These 5 Pharma Bigwigs This Earnings Season?",
      "id": 138333684,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "As earnings season accelerates, pharma heavyweights LLY, MRK, NVO, BMY and PFE prepare to reveal their Q4 results amid a strong sector start.",
      "url": "https://finnhub.io/api/news?id=80649950b33082b20364be17e694b012330a1b2a8b254d291dc2e8103f26dbe0"
    }
  },
  {
    "ts": null,
    "headline": "ACROBiosystems Powers Innovation at bioSeedin's JPM Spotlight, Strategically Supporting Global Partnership Forging",
    "summary": "On January 11, as the global healthcare industry gathered in San Francisco, the BIOSeedin Winter Innovation Partnering Summit successfully convened ahead of J.P. Morgan 2026. ACROBiosystems, as a key strategic partner, joined hands with multiple enterprises to participate in the event.",
    "url": "https://finnhub.io/api/news?id=7b2345a1ae97ae8b6c453576c0681b4d1a8e3823ba6cd04e5c0b84d44ced3a64",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770044400,
      "headline": "ACROBiosystems Powers Innovation at bioSeedin's JPM Spotlight, Strategically Supporting Global Partnership Forging",
      "id": 138332398,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "On January 11, as the global healthcare industry gathered in San Francisco, the BIOSeedin Winter Innovation Partnering Summit successfully convened ahead of J.P. Morgan 2026. ACROBiosystems, as a key strategic partner, joined hands with multiple enterprises to participate in the event.",
      "url": "https://finnhub.io/api/news?id=7b2345a1ae97ae8b6c453576c0681b4d1a8e3823ba6cd04e5c0b84d44ced3a64"
    }
  },
  {
    "ts": null,
    "headline": "Obesity market sales potential tightens as Novo and Lilly enter new era",
    "summary": "STORY: The long-held Wall Street expectation that the global market for obesity drugs would reach $150 billion in the next decade is potentially looking a lot less certain.That's as U.S. prices are falling for GLP-1 treatments from Novo Nordisk and Eli Lilly.And competition heats up in the cash-pay consumer market.Analysts and investors say the fast-changing landscape, which also includes the expected entry of new drugs, has led to a recalculation of what the peak will be.And when those heights may be reached.One portfolio manager said the “peak has come down a little,\" pointing to pricing in the new consumer market and the launch of generic versions of Novo's Ozempic.Unprecedented demand for weight-loss drugs targeting the GLP-1 hormone led analysts to project a market of $150 billion - or even $200 billion - by the early 2030s.But for analysts and investors, 2030 forecasts are around 30% lower and that $150 billion target has shifted to 2035 for some.Dominant players Novo and Lilly both report fourth-quarter financial results on Wednesday.Lilly reached a $1 trillion valuation last year and Novo's new Wegovy weight-loss pill got off to a strong start.According to data, Novo's Wegovy injection and pill and Lilly's Zepbound injection prescriptions totalled 730,000 in the week eding January 23rd.New Wegovy prescriptions grew 4%, largely due to the new pill, while Zepbound was up 0.9%.",
    "url": "https://finnhub.io/api/news?id=df529369948f4209f8f54cfa6cfe2dfd6623bde7cb3f6122443c6682906cb1d6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770041870,
      "headline": "Obesity market sales potential tightens as Novo and Lilly enter new era",
      "id": 138332399,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "STORY: The long-held Wall Street expectation that the global market for obesity drugs would reach $150 billion in the next decade is potentially looking a lot less certain.That's as U.S. prices are falling for GLP-1 treatments from Novo Nordisk and Eli Lilly.And competition heats up in the cash-pay consumer market.Analysts and investors say the fast-changing landscape, which also includes the expected entry of new drugs, has led to a recalculation of what the peak will be.And when those heights may be reached.One portfolio manager said the “peak has come down a little,\" pointing to pricing in the new consumer market and the launch of generic versions of Novo's Ozempic.Unprecedented demand for weight-loss drugs targeting the GLP-1 hormone led analysts to project a market of $150 billion - or even $200 billion - by the early 2030s.But for analysts and investors, 2030 forecasts are around 30% lower and that $150 billion target has shifted to 2035 for some.Dominant players Novo and Lilly both report fourth-quarter financial results on Wednesday.Lilly reached a $1 trillion valuation last year and Novo's new Wegovy weight-loss pill got off to a strong start.According to data, Novo's Wegovy injection and pill and Lilly's Zepbound injection prescriptions totalled 730,000 in the week eding January 23rd.New Wegovy prescriptions grew 4%, largely due to the new pill, while Zepbound was up 0.9%.",
      "url": "https://finnhub.io/api/news?id=df529369948f4209f8f54cfa6cfe2dfd6623bde7cb3f6122443c6682906cb1d6"
    }
  },
  {
    "ts": null,
    "headline": "Novo combination obesity shot meets goal in diabetes trial",
    "summary": "CagriSema’s blood sugar and weight reductions exceeded the company’s blockbuster Wegovy, yet the drug might still struggle to rival Lilly's Zepbound.",
    "url": "https://finnhub.io/api/news?id=41ecd25bfac30b1eaef6600cebe3a10645efd0f2581d7327a112cf56e3dda271",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770040800,
      "headline": "Novo combination obesity shot meets goal in diabetes trial",
      "id": 138335063,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "CagriSema’s blood sugar and weight reductions exceeded the company’s blockbuster Wegovy, yet the drug might still struggle to rival Lilly's Zepbound.",
      "url": "https://finnhub.io/api/news?id=41ecd25bfac30b1eaef6600cebe3a10645efd0f2581d7327a112cf56e3dda271"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly selects Pennsylvania for $3.5bn obesity drugs manufacturing site",
    "summary": "Historically a steel production hub, Lehigh Valley will now help manufacture Lilly’s weight loss drug hopeful retatrutide.",
    "url": "https://finnhub.io/api/news?id=b3b8ca845770622f779dc7d5beb29b3b7a48b39614ca4aaa705ab9538f5e4aa0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770035744,
      "headline": "Eli Lilly selects Pennsylvania for $3.5bn obesity drugs manufacturing site",
      "id": 138331607,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Historically a steel production hub, Lehigh Valley will now help manufacture Lilly’s weight loss drug hopeful retatrutide.",
      "url": "https://finnhub.io/api/news?id=b3b8ca845770622f779dc7d5beb29b3b7a48b39614ca4aaa705ab9538f5e4aa0"
    }
  },
  {
    "ts": null,
    "headline": "Should Investors Buy, Sell or Hold Lilly Stock Ahead of Q4 Earnings?",
    "summary": "LLY heads into Q4 earnings with GLP-1 demand from Mounjaro and Zepbound, as pricing pressure and new oral Wegovy competition loom.",
    "url": "https://finnhub.io/api/news?id=fbe193a0675ae906014f4fb358678ab546df63db5ce390d431c36b749510583f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770034500,
      "headline": "Should Investors Buy, Sell or Hold Lilly Stock Ahead of Q4 Earnings?",
      "id": 138331608,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LLY heads into Q4 earnings with GLP-1 demand from Mounjaro and Zepbound, as pricing pressure and new oral Wegovy competition loom.",
      "url": "https://finnhub.io/api/news?id=fbe193a0675ae906014f4fb358678ab546df63db5ce390d431c36b749510583f"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) Forms Strategic Collaboration with Repertoire Immune Medicines",
    "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 7 Best Low-Risk Dividend Stocks to Invest in. Eli Lilly and Company (NYSE:LLY) discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. According to a January 29 report by Reuters, Eli Lilly and Company (NYSE:LLY) is teaming up with Repertoire […]",
    "url": "https://finnhub.io/api/news?id=8c8674ab78daa3991f98366779f3bdfe11b42e050b8b31bba338069c7bc93244",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770033315,
      "headline": "Eli Lilly and Company (LLY) Forms Strategic Collaboration with Repertoire Immune Medicines",
      "id": 138331609,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 7 Best Low-Risk Dividend Stocks to Invest in. Eli Lilly and Company (NYSE:LLY) discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. According to a January 29 report by Reuters, Eli Lilly and Company (NYSE:LLY) is teaming up with Repertoire […]",
      "url": "https://finnhub.io/api/news?id=8c8674ab78daa3991f98366779f3bdfe11b42e050b8b31bba338069c7bc93244"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly chooses rural Pennsylvania for $3.5B weight-loss drug production",
    "summary": "The development is the fourth announced by the pharmaceutical giant since September as competitors look to reshore operations and upgrade their facilities in the U.S.",
    "url": "https://finnhub.io/api/news?id=625a56464d3225d8888c5615cde6ec916eca9221fea0afb6a8fc717e2613d5fd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770033180,
      "headline": "Eli Lilly chooses rural Pennsylvania for $3.5B weight-loss drug production",
      "id": 138333685,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The development is the fourth announced by the pharmaceutical giant since September as competitors look to reshore operations and upgrade their facilities in the U.S.",
      "url": "https://finnhub.io/api/news?id=625a56464d3225d8888c5615cde6ec916eca9221fea0afb6a8fc717e2613d5fd"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly CEO Says Medicare Coverage Of Obesity Drugs Could Be Game-Changer For Its Weight-Loss Pill",
    "summary": "Medicare's upcoming coverage of obesity treatments could dramatically expand access to Eli Lilly's (NYSE:LLY) experimental weight-loss pill, orforglipron, CEO Dave Ricks said Friday. Medicare Coverage To Unlock Millions Of Patients In an interview with CNBC, Ricks said that the new policy will allow Medicare beneficiaries to access obesity drugs \"immediately following launch\" of the company's highly anticipated experimental weight-loss drug, Orforglipron. With 20 million to 30 million Medicare p",
    "url": "https://finnhub.io/api/news?id=77cbca94f090ad017604dd70aa7572cbffb000c81bb99118cc0fc70dd9a16c7d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770032768,
      "headline": "Eli Lilly CEO Says Medicare Coverage Of Obesity Drugs Could Be Game-Changer For Its Weight-Loss Pill",
      "id": 138330822,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Medicare's upcoming coverage of obesity treatments could dramatically expand access to Eli Lilly's (NYSE:LLY) experimental weight-loss pill, orforglipron, CEO Dave Ricks said Friday. Medicare Coverage To Unlock Millions Of Patients In an interview with CNBC, Ricks said that the new policy will allow Medicare beneficiaries to access obesity drugs \"immediately following launch\" of the company's highly anticipated experimental weight-loss drug, Orforglipron. With 20 million to 30 million Medicare p",
      "url": "https://finnhub.io/api/news?id=77cbca94f090ad017604dd70aa7572cbffb000c81bb99118cc0fc70dd9a16c7d"
    }
  },
  {
    "ts": null,
    "headline": "Analysis-Obesity market sales potential tightens as Novo and Lilly enter new era",
    "summary": "LONDON, Feb 2 (Reuters) - The long-held Wall Street expectation that the global market for obesity drugs would reach $150 billion in the next decade is looking a lot less certain with U. prices falling for GLP-1 treatments from Novo Nordisk and Eli Lilly and competition heating up in the cash-pay consumer market.",
    "url": "https://finnhub.io/api/news?id=2b638efc1239d458f16ddfd0d04c7b3540517c3a1ec3146ae80cab8076aeb009",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770030462,
      "headline": "Analysis-Obesity market sales potential tightens as Novo and Lilly enter new era",
      "id": 138330823,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LONDON, Feb 2 (Reuters) - The long-held Wall Street expectation that the global market for obesity drugs would reach $150 billion in the next decade is looking a lot less certain with U. prices falling for GLP-1 treatments from Novo Nordisk and Eli Lilly and competition heating up in the cash-pay consumer market.",
      "url": "https://finnhub.io/api/news?id=2b638efc1239d458f16ddfd0d04c7b3540517c3a1ec3146ae80cab8076aeb009"
    }
  },
  {
    "ts": null,
    "headline": "Did Lilly's $3.5 Billion Retatrutide Plant Just Recast Eli Lilly's (LLY) Obesity Investment Narrative?",
    "summary": "Eli Lilly and Company recently announced plans to invest more than US$3.50 billion in a new Lehigh Valley, Pennsylvania manufacturing facility that will produce next-generation injectable weight-loss medicines, including the investigational therapy retatrutide, with operations targeted for 2031. By pairing this build-out with advanced AI-enabled manufacturing and a growing network of U.S. plants, Lilly is signaling a long-term commitment to scaling obesity treatments and reinforcing domestic...",
    "url": "https://finnhub.io/api/news?id=2d4da0d73568516cdbd54eda4a9cc23b63c68f71184e0acfbcecff1c95e48836",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770026882,
      "headline": "Did Lilly's $3.5 Billion Retatrutide Plant Just Recast Eli Lilly's (LLY) Obesity Investment Narrative?",
      "id": 138330824,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company recently announced plans to invest more than US$3.50 billion in a new Lehigh Valley, Pennsylvania manufacturing facility that will produce next-generation injectable weight-loss medicines, including the investigational therapy retatrutide, with operations targeted for 2031. By pairing this build-out with advanced AI-enabled manufacturing and a growing network of U.S. plants, Lilly is signaling a long-term commitment to scaling obesity treatments and reinforcing domestic...",
      "url": "https://finnhub.io/api/news?id=2d4da0d73568516cdbd54eda4a9cc23b63c68f71184e0acfbcecff1c95e48836"
    }
  },
  {
    "ts": null,
    "headline": "ABIVAX Société Anonyme (ABVX) Share Momentum Builds Amid Takeover Speculation and Advancing Therapeutic Programs",
    "summary": "ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the 11 Best Performing Stocks in the Last 12 Months. For the past couple of months, speculation has arisen that Eli Lilly, an American multinational pharmaceutical company, is pursuing a potential acquisition of ABIVAX Société Anonyme (NASDAQ:ABVX). However, on January 20, 2026, ABIVAX’s CEO Marc De Garidel dismissed […]",
    "url": "https://finnhub.io/api/news?id=8aa886c25763a473dc1ad2618ce2fb2a0577bf071359f9c7480c349b542b0b9b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770023812,
      "headline": "ABIVAX Société Anonyme (ABVX) Share Momentum Builds Amid Takeover Speculation and Advancing Therapeutic Programs",
      "id": 138330171,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the 11 Best Performing Stocks in the Last 12 Months. For the past couple of months, speculation has arisen that Eli Lilly, an American multinational pharmaceutical company, is pursuing a potential acquisition of ABIVAX Société Anonyme (NASDAQ:ABVX). However, on January 20, 2026, ABIVAX’s CEO Marc De Garidel dismissed […]",
      "url": "https://finnhub.io/api/news?id=8aa886c25763a473dc1ad2618ce2fb2a0577bf071359f9c7480c349b542b0b9b"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Expands Obesity And Gene Programs As Valuation Pulls Back",
    "summary": "Eli Lilly (NYSE:LLY) is committing $3.5b to build a new Pennsylvania facility to produce next generation injectable weight loss drugs. The company also announced a research collaboration with Seamless Therapeutics focused on gene editing approaches for hearing loss. A separate collaboration with Repertoire Immune Medicines aims to develop tolerizing therapies for autoimmune diseases. Eli Lilly enters this news cycle with a current share price of $1,037.15 and a 5 year return of 431.1%. The...",
    "url": "https://finnhub.io/api/news?id=fbbf5ea4bca2b2e8c5ee66e17c60b114144273ac1c125fd2c0b5da1ba097a7e7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770023477,
      "headline": "Eli Lilly Expands Obesity And Gene Programs As Valuation Pulls Back",
      "id": 138330172,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (NYSE:LLY) is committing $3.5b to build a new Pennsylvania facility to produce next generation injectable weight loss drugs. The company also announced a research collaboration with Seamless Therapeutics focused on gene editing approaches for hearing loss. A separate collaboration with Repertoire Immune Medicines aims to develop tolerizing therapies for autoimmune diseases. Eli Lilly enters this news cycle with a current share price of $1,037.15 and a 5 year return of 431.1%. The...",
      "url": "https://finnhub.io/api/news?id=fbbf5ea4bca2b2e8c5ee66e17c60b114144273ac1c125fd2c0b5da1ba097a7e7"
    }
  },
  {
    "ts": null,
    "headline": "Jobs Report, Big Tech and Pharma Earnings: What to Watch This Week",
    "summary": "Earnings season marches on. Two more Magnificent Seven tech companies—Alphabet and Amazon—will report this week, following on the heels of disappointing results from Microsoft that helped send software stocks tumbling.",
    "url": "https://finnhub.io/api/news?id=a3c960b1f15989f8e98d3cbced37cd59212105d1a1e567048fec0391991b33f8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770016421,
      "headline": "Jobs Report, Big Tech and Pharma Earnings: What to Watch This Week",
      "id": 138329655,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Earnings season marches on. Two more Magnificent Seven tech companies—Alphabet and Amazon—will report this week, following on the heels of disappointing results from Microsoft that helped send software stocks tumbling.",
      "url": "https://finnhub.io/api/news?id=a3c960b1f15989f8e98d3cbced37cd59212105d1a1e567048fec0391991b33f8"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones Futures Fall, Bitcoin Dives To Lowest Since 2024; Google, AMD, Amazon, Palantir Due",
    "summary": "Futures fell and Bitcoin tumbled after Indexes tested support and silver dived Friday. Google, AMD, Lilly, Amazon, Palantir loom.",
    "url": "https://finnhub.io/api/news?id=4f6433faec9deb7f0f804612de7983338824b1c808f6ac884a458bbf415a818a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770004675,
      "headline": "Dow Jones Futures Fall, Bitcoin Dives To Lowest Since 2024; Google, AMD, Amazon, Palantir Due",
      "id": 138328762,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Futures fell and Bitcoin tumbled after Indexes tested support and silver dived Friday. Google, AMD, Lilly, Amazon, Palantir loom.",
      "url": "https://finnhub.io/api/news?id=4f6433faec9deb7f0f804612de7983338824b1c808f6ac884a458bbf415a818a"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones Futures: Silver Rebounds After Crash; Google, AMD, Amazon, Palantir Due",
    "summary": "Bitcoin's woes signals a further risk-off shift after Indexes tested support and silver dived. Google, AMD, Lilly, Amazon loom. Google, AMD, Eli Lilly, Amazon and Palantir earnings loom.",
    "url": "https://finnhub.io/api/news?id=01ea6e9e9b975d6ddba954cce1924cead9a2a0d75a90b1dff6731656addce267",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769996013,
      "headline": "Dow Jones Futures: Silver Rebounds After Crash; Google, AMD, Amazon, Palantir Due",
      "id": 138328333,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Bitcoin's woes signals a further risk-off shift after Indexes tested support and silver dived. Google, AMD, Lilly, Amazon loom. Google, AMD, Eli Lilly, Amazon and Palantir earnings loom.",
      "url": "https://finnhub.io/api/news?id=01ea6e9e9b975d6ddba954cce1924cead9a2a0d75a90b1dff6731656addce267"
    }
  }
]